Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors

Abstract

S32 unrelated to therapy, or (5) clonal evolution with ACAs. Blast phase (BP) is defined as 30% or more blasts in peripheral blood or bone marrow, or extramedullary blast proliferation. For the purpose of this study, we designated the emergence phase of ACAs based on the presence or absence of other AP features. In detail, we defined that ACAs emerged in CP when no other AP features were present, and ACAs emerged in AP when ACAs were accompanied with other AP features. 401 Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors Wei Wang, Jorge Cortes, Pei Lin, Michael Beaty, Di Ai, Hesham Amin, Timothy McDonnell, Hagop Kantarjian, L Jeffrey Medeiros, Shimin Hu MD Anderson Cancer Center; Wake Forest Baptist Health Purpose: Chromosome 3q26 abnormalities in acute myeloid leukemia (AML), including inv(3)/t(3;3) and t(3;21), have been Table 1 Clinical characteristics of CML patients with chromosome Parameter A. inv(3)/t(3;3) (n[30) B. t(3;21) (n[20) Sex Male 14 (47%) 15 (75%) Female 16 (53%) 5 (25%) Age (y) Median 54 52 Range 31-80 22-67 Emergence Phase CP 13 (43%) 4 (20%) AP 2 (7%) 4 (20%) BP 15 (50%) 12 (60%) Cytogenetics Sole 14 (47%) 7 (35%) With others 16 (53%) 13 (65%) TKI response 26 15 CCyR 0 (0%) 1 (7%) MMR 0 (0%) 1 (7%) Transplant after ACAs 10 (33%) 8 (40%) F/U(m) Median 13.3 13.6 Range 1.8-88 2.9-131.9 Status at last F/U Dead 24 19 Persistent 4 1